Skip Navigation LinksHome > March 27, 2011 - Volume 25 - Issue 6 > CD4 cell eligibility thresholds: an analysis of the time to...
doi: 10.1097/QAD.0b013e32834625d3
Clinical Science: Concise Communications

CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters

Minga, Albert Ka,b,c; Lewden, Charlottea,b,c; Gabillard, Delphineb,c; Bomisso, Germain Ia; Toni, Thomas-d'Aquina,d; Emième, Arlette Aa,d; Yapo, Vincenta,d; Inwoley, Andréa,d; Salamon, Rogera,b,c; Anglaret, Xaviera,b,c; for the Agence Nationale de Recherches sur le Sida (ANRS) 1220 Primo-CI Study Group

Collapse Box


Background: WHO recommends initiating combination antiretroviral treatment at the minimal CD4 cell threshold of 350 cells/μl. In sub-Saharan Africa, the time for a recently infected patient to reach this threshold is unclear.

Method: We estimated the probability of reaching different CD4 cell thresholds over time in the ANRS 1220 cohort of HIV-1 seroconverters in Côte d'Ivoire. CD4 cell slopes were estimated using a mixed linear model. Probabilities of crossing the 350 and 500 cells/μl CD4 cell thresholds were estimated by the Kaplan–Meier method.

Results: Between 1997 and 2009, 304 recent seroconverters have been enrolled in the Primo-CI cohort (62% men, median baseline age 29 years and median time since the estimated date of seroconversion 9 months). The probability of having a first CD4 cell count below 500 cells/μl was 0.57, 0.72, 0.79 and 0.84 at study entry, 2, 4 and 6 years, respectively. For a first CD4 cell count below 350 cells/μl, these figures were 0.29, 0.40, 0.55 and 0.67. The time for 75% of patients to reach the threshold was 3.0 years for 500 cells/μl and 7.0 years for 350 cells/μl.

© 2011 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.